Novel GLP-1 Cut Heavy Drinking Days in Alcohol Use Disorder

Summary
(MedPage Today) -- The investigational glucagon/GLP-1 dual receptor agonist pemvidutide significantly reduced the number of heavy drinking days (HDDs) per week in patients with moderate-to-severe alcohol use disorder (AUD), the phase II RECLAIM...
Description from Medpagetoday.
Who is covering this
-
Novel GLP-1 Cut Heavy Drinking Days in Alcohol Use Disorder
(MedPage Today) -- The investigational glucagon/GLP-1 dual receptor agonist pemvidutide significantly reduced the number of heavy drinking days (HDDs) per week in patients with moderate-to-severe alcohol use disorder (AUD), the phase II RECLAIM...
Comments
Comments need JavaScript.